genedx.com - WGS Enterprise Value to EBITDA Ratio
Surging demand for high-precision newborn testing is driving rapid growth for GeneDx Holdings Corp. (WGS), as evidenced by the company's EV/EBITDA ratio adjusted for debt load. The value of 0.00 aligns with the current metric. While a unique DNA database and strict CLIA standards form the business foundation, high R&D expenditures and insurance reimbursement risks are hindering the path to net profitability.
GeneDx (WGS) - metric breakdowns and financial figures
- stock price and consensus target price:
- issuer market value details:
- business book valuation details:
- debt and solvency information:
- financial results and valuation multiples details:
WGS - Annual Net Income|Expected Profit GeneDx Holdings Corp.|WGS - Business Payback Period|Projected Price to Earnings GeneDx|WGS - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple GeneDx Holdings Corp.|WGS - Operating profit before deduction of amortization|Earnings per share for the last twelve months GeneDx|WGS - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months genedx.com|WGS - Earnings per share increase in current year|Net earnings per share growth forecast for next year GeneDx Holdings Corp.
- company sales and revenue statistics:
Fundamental company valuation:genedx.com WGS
Investors use this metric to determine the fair value of a business by comparing the total cost of acquiring the asset, including debt, against its operational profitability. The EV/EBITDA ratio highlights the resilience of GeneDx Holdings Corp. (WGS), whose unique exome database and inelastic demand ensure high margins, a trend clearly reflected in the EV/EBITDA ratio dynamics.
Analysis of competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempus AI TEM|qiagen.com (QGEN) - Company Value to EBITDA|IONS: Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Multiple Repligen (RGEN)|RNA (Avidity) - Enterprise Value to EBITDA Ratio|CRISPR Therapeutics AG - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ultragenyx|Company Value to EBITDA beamtx.com BEAM|Enterprise Value to EBITDA Ratio SRPT (Sarepta Therapeutics, Inc.)|TWST - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 10x TXG|Enterprise Value to Operating Income Before Depreciation Ratio NTLA (Intellia)|Stoke Corp - EV/EBITDA Multiple|BLFS: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|WVE: EV/EBITDA Multiple|Company Value to EBITDA Maze Tx (MAZE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sionna Therapeutics|Enterprise Value to Operating Income Before Depreciation PRME (Prime Medicine Corp)|EV/EBITDA Multiple TSHA|EV/EBITDA Multiple uniqure.com (QURE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MeiraGTx PLC MGTX|Business Value to Operating Income Before Depreciation RGNX|solidbio.com - EV/EBITDA Multiple|OCGN (Ocugen Pharma) - Enterprise Value to Operating Income Before Depreciation|PACB: EV/EBITDA Multiple|Benitec Biopharma (BNTC) - EV/EBITDA Multiple|DSGN (Design Therapeutics Inc) - EV/EBITDA Multiple|Rocket Pharmaceuticals, Inc. (RCKT) - Total Company Value to Operating Income Before Depreciation Ratio|FDMT - Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LXEO (Lexeo)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization korrobio.com KRRO|Total Company Value to Operating Income Before Depreciation Ratio Editas Medicine, Inc. (EDIT)|SLN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio ProQR PRQR|CDXS: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Sangamo BioSciences SGMO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nautilus Bio|MGX (Metagenomi, Inc.) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple DTIL|Generation Bio - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLD (Boundless Bio Inc.)|Business Value to Operating Income Before Depreciation XCUR|Imunon Inc - EV/EBITDA Multiple|PHIO (phiopharma.com) - Enterprise Value to Operating Income Before Depreciation|MBIO (mustangbio.com) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation RNAZ|BNGO (Bionano) - EV/EBITDA Multiple|EV/EBITDA Multiple Applied DNA Corp|EV/EBITDA Multiple BLUE|EV/EBITDA Multiple ImmunoPrecise Antibodies Ltd. (IPA)|EV/EBITDA Multiple OMGA (omegatherapeutics.com)|OMIC: Enterprise Value to Operating Income Before Depreciation|RGLS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SYRS (Syros Pharmaceuticals, Inc)|TBIO: EV/EBITDA Multiple|TRACON Pharmaceuticals (TCON) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology, Inc
